Yale Cancer Center | Strategic Alliance Partners

February 05, 2024

Non-small cell lung cancer, with an EGFR mutation, tends not to respond well to immunotherapy treatments, including durvalumab.

January 31, 2024

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

January 15, 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

January 12, 2024

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

January 10, 2024

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

January 08, 2024

Anne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.

January 05, 2024

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

December 10, 2023

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

December 01, 2023

Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.

November 27, 2023

Michael Hurwitz, MD, PhD, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

November 10, 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

November 02, 2023

Sarah Goldberg, MD, MPH, highlights the mechanism of action of VIC-1911, expands on its ongoing investigation in the phase 1 trial, and sheds light on next steps planned for the agent’s investigation in KRAS G12C–mutant non–small cell lung cancer.

October 26, 2023

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

October 17, 2023

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

October 10, 2023

Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.

October 09, 2023

Oncology experts discuss the platinum chemotherapy shortage in the United States.

September 28, 2023

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

September 15, 2023

Daniel P. Petrylak, MD, discusses the potential uses for erdafitinib, highlighting key studies evaluating the use of the agent in patients with metastatic urothelial cancer.

August 30, 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

August 28, 2023

Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.